Innovation | Novartis United States of America

Media Release
May 07, 2011
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Media Release
Sep 16, 2011
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
Media Release
Aug 01, 2011
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
Media Release
Jul 01, 2011
Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Media Release
Sep 26, 2011
Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
Media Release
Sep 25, 2011
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Media Release
Sep 23, 2011
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Media Release
Dec 13, 2011
Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
Media Release
Dec 12, 2011
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Media Release
Nov 07, 2011
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Media Release
Apr 03, 2012
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
Media Release
Mar 19, 2012
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease

‹ Previous page
1
…
29
30
31
32
33
34
35
…
49
› Next page